Absci Corporation (ABSI)
NASDAQ: ABSI · Real-Time Price · USD
3.030
+0.090 (3.06%)
At close: Jan 29, 2026, 4:00 PM EST
3.050
+0.020 (0.66%)
After-hours: Jan 29, 2026, 7:53 PM EST
Absci Revenue
Absci had revenue of $378.00K in the quarter ending September 30, 2025, a decrease of -77.78%. This brings the company's revenue in the last twelve months to $2.82M, down -33.09% year-over-year. In the year 2024, Absci had annual revenue of $4.53M, down -20.71%.
Revenue (ttm)
$2.82M
Revenue Growth
-33.09%
P/S Ratio
137.60
Revenue / Employee
$17,930
Employees
157
Market Cap
455.63M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.53M | -1.18M | -20.71% |
| Dec 31, 2023 | 5.72M | -29.00K | -0.50% |
| Dec 31, 2022 | 5.75M | 965.00K | 20.18% |
| Dec 31, 2021 | 4.78M | 2.00K | 0.04% |
| Dec 31, 2020 | 4.78M | 2.72M | 132.04% |
| Dec 31, 2019 | 2.06M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ADC Therapeutics | 75.21M |
| Assembly Biosciences | 37.19M |
| Aclaris Therapeutics | 15.74M |
| PureTech Health | 6.39M |
| 4D Molecular Therapeutics | 120.00K |
| vTv Therapeutics | 17.00K |
ABSI News
- 14 days ago - Absci Corporation (ABSI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 6 weeks ago - Absci to Participate in the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Absci Corporation (ABSI) Discusses ABS-201 Program and Clinical Approach for Androgenetic Alopecia Transcript - Seeking Alpha
- 7 weeks ago - Absci Reports New Human Ex Vivo Data Demonstrating That ABS-201™ Stimulates Hair Growth and Regenerates Stem Cell Niche to Potentially Reverse Follicle Miniaturization - GlobeNewsWire
- 7 weeks ago - Absci and U.S. Soccer Legend Landon Donovan Partner to Champion the Patient Voice in Hair Loss Research - GlobeNewsWire
- 2 months ago - Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic Alopecia - GlobeNewsWire
- 2 months ago - Absci Corporation (ABSI) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 2 months ago - Absci Corporation (ABSI) Q3 2025 Earnings Call Transcript - Seeking Alpha